Research programme: rheumatoid arthritis therapy - Wyeth
Alternative Names: B-cell depletion therapies; Calicheamicin-anti-CD22 MAb conjugate; CD22/CalLatest Information Update: 10 Aug 2009
At a glance
- Originator Wyeth
- Class Aminoglycosides; Enediynes; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action CD22 antigen inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 10 Aug 2009 Discontinued - Preclinical for Rheumatoid arthritis in USA (unspecified route)
- 13 Jun 2005 Preclinical trials in Rheumatoid arthritis in USA (unspecified route)